Photosensitizers in prostate cancer therapy.
Photosensitizers in prostate cancer therapy.
复制标题
DOI：
10.18632/oncotarget.15496
复制
发表时间：
2017-05-02
期刊：
影响因子：
--
通讯作者：
Munirathinam G
中科院分区：
文献类型：
--
作者：
Gheewala T;Skwor T;Munirathinam G
目前正在寻找治疗前列腺癌的新疗法，重点是治疗的危害和益处之间的平衡。新的疗法正在不断开发，以提供类似于激进疗法的治疗，副作用有限。光动力疗法（PDT）是一种有前途的策略，在提供局灶治疗原发性前列腺癌以及放疗后。PDT涉及通过适当波长的光激活光敏剂（PS），产生瞬时水平的活性氧（ROS）。近年来，针对前列腺癌的治疗，已开发出mTHPC、motexafin lutetium、padoporfin等光敏剂，本文将对这些新开发的用于前列腺癌治疗的光敏剂进行综述，并沿着其潜在的优势和不足。
The search for new therapeutics for the treatment of prostate cancer is ongoing with a focus on the balance between the harms and benefits of treatment. New therapies are being constantly developed to offer treatments similar to radical therapies, with limited side effects. Photodynamic therapy (PDT) is a promising strategy in delivering focal treatment in primary as well as post radiotherapy prostate cancer. PDT involves activation of a photosensitizer (PS) by appropriate wavelength of light, generating transient levels of reactive oxygen species (ROS). Several photosensitizers have been developed with a focus on treating prostate cancer like mTHPC, motexafin lutetium, padoporfin and so on. This article will review newly developed photosensitizers under clinical trials for the treatment of prostate cancer, along with the potential advantages and disadvantages in delivering focal therapy.